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Introduction
Acute myeloid leukemia (AML) is a heterogeneous clonal
neoplasm characterized by accumulated genetic aberrations,
which result in enhanced proliferation, blocked differentia-
tion and increased survival of the leukemic blast cells and a
variable response to therapy.1,2 In the past decades a number
of recurrent cytogenetic abnormalities have been identified in
AML, such as the chromosomal aberrations t(8;21) and
inv(16).1,2 These recurrent molecular lesions result in expres-
sion of fusion proteins of which the leukemic potential, in
combination with additional genetic events, has been demon-
strated in both in vitro and in vivomodels.3 In addition to cyto-
genetic abnormalities, acquired mutations in disease genes,
such as FLT3, NPM1, RUNX1 and CEBPA, have recently been
demonstrated to be involved in AML as well.1,2 Several
acquired molecular aberrations carry prognostic value and
have been incorporated in routine molecular analyses of
AML.1,2
Nowadays, various genome-wide approaches, such as gene
expression profiling, genome-wide genotyping and next-gen-
eration sequencing, enable detailed analyses of hematologic
malignancies to identify novel pathogenic genes.2,4,5 Examples
of aberrations in myeloid proliferative malignancies revealed
with these novel technologies are mutations in the genes
IDH1, TET2, DNMT3A, ASXL1, and EZH2.6-11
Besides balanced translocations, large chromosomal regions
showing losses or gains of genetic material are apparent in the
leukemic blasts of AML patients, e.g., those involving chro-
mosome 5 and 7.1 In the past two decades, attempts to iden-
tify the tumor suppressor genes located on these chromo-
somes have failed. Through genome-wide single nucleotide
polymorphism genotyping it has become possible to simulta-
neously genotype hundreds of thousands of single nucleotide
polymorphisms in a single assay. In addition, single
nucleotide polymorphism platforms can also be conveniently
used to determine chromosomal copy numbers, similarly to
array comparative genomic hybridization. Genomic DNA
can be examined with an inter-marker distance of several
hundreds of base pairs, which makes it feasible to detect
(micro) deletions and/or amplifications that are missed with
conventional cytogenetics. The application of high-through-
put single nucleotide polymorphism genotyping has been ele-
gantly demonstrated to be powerful for the identification of
disease genes, such as those for acute lymphoblastic
leukemia4,12,13 or AML.14 Another major advantage of single
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Acute myeloid leukemia is a neoplasm characterized by recurrent molecular aberrations traditionally demonstrated
by cytogenetic analyses. We used high density genome-wide genotyping and gene expression profiling to reveal
acquired cryptic abnormalities in acute myeloid leukemia. By genome-wide genotyping of 137 cases of primary
acute myeloid leukemia, we disclosed a recurrent focal amplification on chromosome 14q32, which included the
genes BCL11B, CCNK, C14orf177 and SETD3, in two cases. In the affected cases, the BCL11B gene showed consis-
tently high mRNA expression, whereas the expression of the other genes was unperturbed. Fluorescence in situ
hybridization on 40 cases of acute myeloid leukemia with high BCL11BmRNA expression [2.5-fold above median;
40 out of 530 cases (7.5%)] revealed 14q32 abnormalities in two additional cases. In the four BCL11B-rearranged
cases the 14q32 locus was fused to different partner chromosomes. In fact, in two cases, we demonstrated that the
focal 14q32 amplifications were integrated into transcriptionally active loci. The translocations involving BCL11B
result in increased expression of full-length BCL11B protein. The BCL11B-rearranged acute myeloid leukemias
expressed both myeloid and T-cell markers. These biphenotypic acute leukemias all carried FLT3 internal tandem
duplications, a characteristic marker of acute myeloid leukemia. BCL11B mRNA expression in acute myeloid
leukemia appeared to be strongly associated with expression of other T-cell-specific genes. Myeloid 32D(GCSF-R)
cells ectopically expressing Bcl11b showed decreased proliferation rate and less maturation. In conclusion, by an
integrated approach involving high-throughput genome-wide genotyping and gene expression profiling we identi-
fied BCL11B as a candidate oncogene in acute myeloid leukemia.
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ABSTRACT
nucleotide polymorphism arrays is the fact that allele loss-
es are directly recognizable as loss-of-heterozygosity. In
fact, single nucleotide polymorphism arrays revealed that
approximately 20% of cases of AML exhibit large non-
random regions of homozygosity without changes in
copy number as a result of segmental uniparental disomy,
often indicating mutations in genes within these regions.
These areas of uniparental disomy have been associated
with mutations in CEBPA, WT1, FLT3 and RUNX1.15,16 
In addition, deletion, amplification and uniparental dis-
omy may have other important consequences, such as
those on gene expression. Juxtaposition of regulatory
sequences may result in increased or decreased expression
of affected genes. Thus, genome-wide analyses to detect
copy number changes and loss of heterozygosity in the
context of gene expression may also point towards patho-
genic genes. We recently developed SNPExpress, an easily
accessible software tool to analyze single nucleotide poly-
morphism genotype calls, copy number and gene expres-
sion in an accurate, efficient combinatorial way.17
In this study, we identified BCL11B as the candidate
oncogene in AML through an integrated approach of
genome-wide genotyping and gene expression profiling,
followed by next-generation sequencing. BCL11B is a
Kruppel family zinc finger family gene located at 14q32,
associated with transcriptional co-repressor complexes in
mammalian cells and a pivotal regulator of differentiation
and survival of hematopoietic cells, especially T cells.18 We
demonstrated that BCL11B is involved in a number of
cryptic 14q32 translocations in AML, in which BCL11B
and T-cell associated genes expression levels are increased
concomitantly. Overexpression of BCL11B in a murine
myeloid cell line model inhibits proliferation.
Methods
Patients’ samples
This study was approved by our local Medical Ethical
Committee (MEC-2004-030 and MEC2007-364). After informed
consent, bone marrow aspirates or peripheral blood samples were
collected from a representative cohort of AML patients. Eligible
patients had a diagnosis of primary AML, confirmed by cytologi-
cal examination of blood and bone marrow. All patients were
treated according to HOVON (Dutch-Belgian Hematology-
Oncology Co-operative group) protocols (http://www.hovon.nl).
Further details are available in the Online Supplementary Appendix.
Genome-wide genotyping and gene expression profiling
Genome-wide genotyping data sets of 48 patients with various
subtypes of AML were generated using Affymetrix 500K NspI/StyI
DNA mapping arrays and of 89 patients with cytogenetically nor-
mal AML using Affymetrix 250K NspI or StyI DNA Mapping
arrays. The copy numbers of all AML samples were calculated
using diploid references, i.e., 15 normal karyotype AML samples.
Further details are available in the Online Supplementary Appendix.
Gene expression profiles of the same AML cases were generat-
ed using Affymetrix HG-U133 plus 2.0, as described elsewhere
(GEO Series accession number GSE6891).19 Pearson correlation
analyses were performed as described previously.20
The genome-wide genotyping and gene expression profiling
data sets were examined using SNPExpress.17
Fluorescence in situ hybridization
Dual color fluorescence in situ hybridization (FISH) was per-
formed with BAC clones RP11-431B1, RP11-876E22, RP11-830F3,
RP11-782I5, RP11-450C22, RP11-57E12, RP11-1069L3 and RP11-
242A7 covering the BCL11B region and regions up- and down-
stream (BACPAC resources, Oakland, USA). Further details are
available in the Online Supplementary Appendix. 
Targeted sequencing of the 14q32 genomic region
Library preparation and targeted re-sequencing was performed
following previously described protocols.21 In brief, high molecular
weight DNA from AML #2301 and #7073 was sheared using a
Covaris E210 waterbath sonificator. The BCL11B 14q32 - tel
genomic region [chr14:93930247-105928955 (hg19)] was captured
with a Roche/Nimblegen SeqCap EZ Choice XL Library. The cap-
tured region was subsequently paired-end sequenced using
Illumina HiSeq2000. The data were analyzed using an in-house
pipeline, including visualization with IGV, which identifies single
nucleotide variants, small and large indels and copy number vari-
ations. The chromosomal breakpoints were identified using
Breakdancer22 in the 14q32 region and the partner chromosome.
The genomic fusions were subsequently confirmed by Sanger
sequencing.
Western blot analyses
Western blot analyses were carried out using affinity-purified
rabbit polyclonal anti-BCL11B antibody (Novus Biologicals,
Littleton, USA). Immune complexes were detected by binding
anti-mouse IgG conjugated to horseradish peroxidase (DAKO,
Heverlee, Belgium) followed by an enhanced chemiluminescence
assay (Amersham Bioscience, Piscataway, NJ, USA) and GAPDH
was stained with primary affinity-purified rabbit polyclonal anti-
body (α-GAPDH FL-335) (Santa Cruz Biotechnology, California,
USA). Further details are available in the Online Supplementary
Appendix.
DNA constructs and generation of BCL11B-expressing
32D/GCSFR cells
A murine Bcl11b cDNA (kindly donated by Dorina Avram,
Albany Medical Center, Albany, NY, USA) was subcloned into a
pLXSN expression vector under the control of the 5’ long terminal
repeat of the Moloney murine sarcoma virus (Clontech,
Mountainview, USA). Vector constructs were confirmed by
nucleotide sequencing and retrovirally transfected into 32D cells
that stably express human granulocyte colony-stimulating factor
receptor (GCSF-R)23 using Fugene transfection reagent (Roche,
Indianapolis, USA). Cells were stimulated with interleukin-3 (25
ng/mL) or granulocyte colony-stimulating factor (25 ng/mL),
counted and assessed for proliferation and granulocytic differenti-
ation. Further details are available in the Online Supplementary
Appendix.
Results
Genome-wide genotyping of cytogenetically abnormal
and normal cases of acute myeloid leukemia
In total, DNA mapping array profiles of 137 patients
with AML were generated (Figure 1). Initially a subgroup
of 48 AML samples was selected based on previous gene
expression profiling studies, i.e., 21 AML cases from gene
expression profiling clusters #4 and #15 (100% CEBPA
mutant or CEBPA silenced24), 13 AML cases from cluster
#9 [100% inv(16)] and 14 AML cases from cluster #10
(adverse prognosis).20 In addition, DNA mapping array
profiles, i.e., Affymetrix 250K NspI or StyI DNA mapping
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array, of 89 AML cases with normal karyotypes were gen-
erated.
With the Affymetrix 500K NspI/StyI DNA Mapping
arrays, all known numerical cytogenetic aberrations, i.e.,
whole chromosome and interstitial deletions and amplifi-
cations that had been identified with cytogenetic banding
analysis, were recognized in the 48 cytogenetically abnor-
mal AML samples, as long as the abnormalities were pres-
ent in over 30% of the AML cells.17 Also, in approximately
25% of all cases large regions of segmental uniparental dis-
omy were detected, often involving whole chromosome
arms.17
In addition to the known cytogenetic aberrations, rela-
tively low numbers of small interstitial deletions and
amplifications were detected in the 137 AML cases.
However, some of these were indicative of the presence of
cryptic translocations, such as cryptic t(5;11), t(9;22) and
t(4;11), which are known to encode chimeric fusion pro-
teins essential for leukemogenesis. All fusion transcripts
involved in these translocations, i.e., NUP98-NSD1,25
BCR-ABL and MLL-AF4, were confirmed by reverse tran-
scriptase polymerase chain reaction analysis. Thus,
although relatively small numbers of aberrations were
found, most being non-recurrent, they may reliably tag
relevant leukemic lesions.
Integrated analysis of genome-wide genotypes 
and gene expression profiles
By an integrated approach using the genome-wide
genotyping data and previously determined gene expres-
sion profiles of the primary AML samples (Figure 1),20 we
searched for genes aberrantly expressed as a result of
numerical changes in the AML genome. Using
SNPExpress,17 we identified two AML cases with relative-
ly small interstitial amplifications in the 14q32 region
(#2301 amplification: 482 Kb, 3 copies and #7073 amplifi-
cation: 460 Kb, 3 copies) (Figure 2A,B). The amplified
region encompassed the genes BCL11B, CCNK, C14orf177
and SETD3. Interestingly, BCL11B mRNA was highly
expressed in the two AML cases with numerical changes,
whereas the expression of C14orf177, CCNK and SETD3
were not affected as compared to other AML cases (Figure
2A,B). In addition, BCL11B mRNA was highly expressed
in AML #2301 and #7073, whereas expression was low or
absent in control AML cases (Figure 2A). This could indi-
cate that BCL11B becomes overexpressed as a result of a
genomic rearrangement in these AML cases. The small
interstitial amplifications in AML #2301 and #7073 may
point towards cryptic translocations, as was seen in AML
cases carrying the cryptic translocations t(5;11), t(9;22) and
t(4;11).
Fluorescence in situ hybridization reveals translocations
in acute myeloid leukemia #2301 and #7073 involving
BCL11B
To confirm the amplifications in the BCL11B locus in
the two AML cases, we performed FISH analysis with a
probe covering the BCL11B gene (RP11-431B1) and a
probe flanking this locus (RP11-74H1) (Figure 3A). On
metaphase spreads of both AML cases an additional
BCL11B allele was apparent (Figure 3B). This is in line
with the expected copy number change for the BCL11B
locus (n=3) as shown with SNPExpress (Figure 2A,B). In
fact, through verification using chromosomal paints we
showed that BCL11B was translocated to chromosome 6
in AML case #2301 and chromosome 8 in AML #7073
(data not shown).
Amplified 14q32 genomic regions are integrated 
into transcriptionally active loci  
We performed 14q32 capture sequencing on AML cases
#2301 and #7073. Paired-end sequencing of the captured
region on the Illumina HiSeq2000 in AML case #2301 and
case #7073 revealed the partner chromosomal regions on
chromosome 6 and 8, respectively. Paired-end reads span-
ning 14q32 and chr6q25.3 (chr6:156717480 and
chr14:99110325; chr6:156587275 and chr14:99748893)
were identified in AML case #2301 and reads spanning
14q32 and 8q24.21 (chr8:130485869 and chr14:99179210)
in case #7073. These breakpoints were confirmed by poly-
merase chain reaction analysis of genomic DNA, followed
by Sanger sequencing. The BCL11B encoding-amplified
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Figure 1. Research design. GEP: gene expression profiling.
DNA integrated into two transcriptionally active regions
on chromosomes 6 and 8, i.e., on 6q25.3 into an expressed
sequence tag sequence CB984582  and on 8q24.21 into the
large non-coding RNA gene Coiled-Coil Domain
Containing 26 (CCDC26). Both polyA genes were tran-
scriptionally active in the two cases of AML, and various
other AML cases, and are subjected to mRNA splicing as
demonstrated by RNA sequencing on an Illumina
HiSeq2500 (data not shown), indicating that these RNA are
expressed in myeloid cells. No fusion transcripts between
BCL11B and RNA encoded by the partner chromosomes
could be detected by RNAseq, suggesting that regulatory
sequences on chr6q25.3 and 8q24.21 may activate the
BCL11B gene in the BCL11B-rearranged AML cases.
Acute myeloid leukemia case #2301 expresses 
full-length BCL11B
The translocations involving BCL11B could result in
increased expression of either full-length BCL11B or a
fusion protein involving BCL11B. In fact, BCL11B mRNA
expression in AML#2301 and AML#7073, were, respec-
tively, 12- and 8-fold over mean BCL11B mRNA expres-
sion in 530 AML cases (219528_s_at; 22895_s_at;
224310_s_at).19 Next, we examined the expression profiles
BCL11B, a novel putative oncogene in AML
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Figure 2. Identification of interstitial amplifications on 14q32.2 using SNPExpress. (A) Sequential alignment of the genotypes with copy num-
bers from the Affymetrix DNA mapping array of chromosome 14q32.2 of four AML samples.17 The copy numbers are shown for each individual
patient by horizontal lines (n=0, 1, 2, 3, 4). The single nucleotide polymorphism genotypes are sequentially aligned along the chromosome
(AA: red; BB: yellow; AB: blue, no call: white). Gains (default n>2.5) are depicted as the pink background. Gene expression levels are visualized
as vertical white bars at the chromosomal position of the gene-specific probe set. In the event that multiple probe sets span the same region
in the chromosome-wide view the vertical gene expression bars are green and proportional to the highest expression value. The green boxes
represent exons of the encoded genes, and the arrows indicate the orientation. In AML #2301 and AML #7073 clear amplifications are visible,
whereas these aberrations are absent in the two control case of AML. (B) Snapshot of SNPExpress illustrating the amplified region in AML
cases #2301 and #7073 from Figure 2A, showing the genes located within the amplified regions. C14orf177 and BCL11B are amplified in
both AML cases, whereas SETD3 and CCNK are amplified only in AML #7073. BCL11B expression is increased in AML #2301 and #7073 as
indicated by the green bar (multiple probe sets), whereas BCL11B expression is absent in control AML cases (Figure 2A).
A
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obtained with Affymetrix Human Exon 1.0 ST Array for
AML case #2301. This analysis showed that in AML
#2301 all four exons of BCL11Bwere expressed at similar-
ly high levels (data not shown). The fact that exon 1 of
BCL11B, containing the ATG start codon, was expressed
suggested that full-length BCL11B is expressed rather than
a fusion protein in which parts of BCL11B are involved. 
Protein lysates of AML case #2301 were available for
western blot analyses. With western blot analyses of
whole, cytoplasmic and nuclear cell lysates of AML #2301
we assessed both the size and localization of the BCL11B
protein. Immunodetection with BCL11B antibodies con-
firmed the expression of full-length BCL11B protein
(Figure 4). Moreover, BCL11B expression appeared to be
restricted to the nucleus. Of note, full-length BCL11B was
also highly expressed in AML case #2238, an AML with-
out any known aberration involving BCL11B.
Fluorescence in situ hybridization analyses of selected
acute myeloid leukemia cases with high BCL11B mRNA
expression reveals additional cases with BCL11B
translocations  
The fact that FISH analysis of AML cases showing high
expression of BCL11B mRNA revealed translocations
involving BCL11B raised the possibility that other AML
cases with aberrantly high BCL11B expression would also
harbor translocations involving BCL11B. Gene expression
profiling of 530 AML cases19 showed variable expression
of BCL11B mRNA in subsets of AML, including case
#2301 and #7073 (Figure 5A). Interestingly, AML cases
with high BCL11B expression appear to cluster in several
distinct clusters (Figure 5A), suggesting that BCL11B over-
expression is associated with distinct AML subtypes. We
selected 40 AML cases with increased BCL11B mRNA
expression, i.e., >2.5-fold above mean BCL11B expression
in primary AML (Figure 5A), and performed FISH analysis
on the BCL11B chromosomal region.
FISH analyses revealed two additional AML cases with
a BCL11B translocation (AML #6366 and #6451) (Figure
5A,B). With specific chromosomal paints, we showed that
in AML case #6451 the BCL11B locus was translocated to
chromosome 7 (data not shown). Further FISH could not be
carried out on AML #6366 due to a lack of material.
Immunophenotyping and molecular analyses of acute
myeloid leukemia cases carrying BCL11B aberrations
Immunophenotyping the AML cases demonstrated that
those with BCL11B translocations expressed not only
myeloid markers, but also lymphoid markers such as
CD2, CD3, and CD7 (Table 1). Cytoplasmic CD3 expres-
sion was present in case #2301, suggesting that it may bet-
ter correspond to a T-acute lymphoblastic leukemia, but
cytoplasmic CD3 was absent in the remaining cases. In
fact, these AML cases appeared to have a biphenotypic
signature, i.e., expressing (early) myeloid as well as T-cell-
associated markers.
Well-known recurrent molecular abnormalities were
searched for in the AML cases carrying BCL11B aberra-
tions. These analyses demonstrated, with no exception,
that these AML cases carried mutations in the FLT3 gene,
i.e., FLT3 internal tandem duplications (ITD) in all cases
and one case had a concurrent FLT3 mutation in the tyro-
S. Abbas et al.
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Figure 3. FISH analysis of AML cases
#2301 and #7073 using probes spe-
cific for BCL11B and flanking
BCL11B. (A) Schematic representa-
tion of the fluorescein isothio-
cyanate-labeled BAC probe (RP11
431B1) covering the BCL11B locus
and Texas red-labeled BAC probe
(RP11 242A7) covering the region
adjacent to BCL11B. (B) Microscope
images of FISH analysis performed
on metaphase chromosomes of
AML cases #2301 and #7073 show-
ing additional green signal
(RP11431B1) indicative of an extra
copy of the BCL11B locus.
Figure 4. Western blot analysis of BCL11B in AML case
#2301. Western blot analysis with a BCL11B-specific anti-
body demonstrates high expression of full-length BCL11B in
AML case #2301, in the nuclear compartment (upper
panel). Whole cell lysates from Jurkat, an acute T-cell
leukemia cell line, and AML #2238 show high BCL11B
expression. AML cases #2195 and #2240 with low BCL11B
mRNA expression were used as negative controls
(#2301w:whole cell lysate; #2301c: cytoplasmic lysate;
#2301n: nuclear lysate). β-actin was used as a loading con-
trol (lower panel).   
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sine kinase domain (TKD) (Table 1). We did not identify
mutations in K-RAS, N-RAS, c-KIT, IDH1, IDH2, ASXL1
or CEBPA in the AML cases carrying a BCL11B abnormal-
ity. Case #6366 also carried a DNMT3A mutation (Table
1).
We analyzed the immunophenotype of the BCL11B
non-rearranged cases with BCL11B overexpression and
did not find a specific pattern of T-cell specific markers.
Several cases did express CD7, but this aberrant marker is
relatively frequently present in AML (present in approxi-
mately 30% of cases). Moreover, we were unable to
demonstrate a significant association between BCL11B
overexpression and FLT3-ITD or -TKD mutations in
BCL11B non-rearranged cases of AML.
BCL11B, a novel putative oncogene in AML
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Table 1. Clinical, molecular and immunophenotypic data of the AML cases with BCL11B translocations. The mutation status for FLT3, NPM1, N-RAS, K-
RAS, CEBPA, c-KIT, ASXL1, IDH1, IDH2 and DNMT3A was determined as described previously.47-49 No mutations were present in NPM1, N-RAS, K-RAS,
CEBPA, KIT, ASXL1, IDH1, and IDH2 in the four AML cases (pos: mutant; neg: wild-type). 
Patient number AML #2301 AML #7073 AML #6451 AML #6366
FLT3 ITD pos pos pos pos
FLT3 TKD835 neg neg pos neg
DNMT3Amutation neg neg neg pos
FAB subtype M1 M4 M1 M2
WHO 1 WHO 1 WHO 2 WHO 0 WHO
Gender male male female female
Karyotype 46,XY[21]/ 46,XY[20] 46,XX,del(7)(q21q35)[5]/ 53,XX,+4,+8,+10,+13,
?46,XY,inc[9] 46,idem,add(13)(q3?4)[17]/ +14,+15,+20[4]/
46,idem,add(9)(q3?4)[2]/ 46,XX[35]
46,XX[15]
Immunophenotype CD45(+),HLA-DR-,CD34+, CD15partial+,CD33+,CD7+, CD45(+),HLA-DR+,CD34+, CD45(+),HLA-DR+, 
TdT+,MPOpartial+,CD1-, CD36partial+,CD56-,CD65s-, TdTpartial+,MPOpartial+, CD34partial+,TdT-, 
CD2+,CD3+,CD4-,CD5- CD117partial+,CD133+, CD11c-,CD13+,CD15-, MPOpartial+,CD11c partial+, 
CD4partial+ CD15s partial+,CD33-, CD13partial+,CD15partial+,
CD65s-,CD117+,CD133+, CD33+,CD36partial+, 
CD2+,CD7partial+ CD117 partial+, CD133+,
CD4 partial+, CD7(+) 
Figure 5. Correlation view based on
gene expression profiling of 530 AML
cases.19 (A) Pearson correlation view of
530 AML cases showing gene expres-
sion correlation based on 2847 probe
sets. The black bars indicate expression
of BCL11B 1: BCL11B expression:
219528_s_at and 2: BCL11B expres-
sion: 222895_s_at, where the size of
the bars is proportional to the levels of
BCL11B expression; 3: selected AML
with BCL11B overexpression (>2.5-fold
mean). The BCL11B-rearranged cases
#2301, #6451, #6366 and #7073 are
indicated by arrows. (B) FISH analysis
performed on metaphase spreads of
AML case #6451 showing disassocia-
tion of the probe RP11242A7 (red) and
RP11431B1 (green) indicating translo-
cation of BCL11B. 
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BCL11B is aberrantly expressed in acute myeloid
leukemia and associated with the T-cell gene 
expression signature 
To investigate whether other AML cases with elevated
BCL11B mRNA expression show full-length BCL11B
expression, we carried out western blot analyses on a
number of AML cases with high BCL11B mRNA expres-
sion. All analyzed samples with high BCL11B mRNA
showed full-length BCL11B protein expression at variable
levels (Figure 6). Because of the lack of specimens, BCL11B
protein expression analyses in non-rearranged BCL11B
cases was limited to those shown in Figures 4 and 6.
To examine which genes are co-expressed with BCL11B
in AML, we performed a Pearson correlation analysis
using Affymetrix gene expression profiling data from 530
AML cases.19 BCL11B co-regulated probe sets were calcu-
lated across all AML patients. The top 50 BCL11B correlat-
ing probe sets are highly associated with T cells and T-cell
development (Online Supplementary Table S1). In fact, the
majority of BCL11B-associated genes are T-cell specific
genes, with CD3, TRBV19, IL32, LCK, TCF7 and CD2
being just a few examples among many others (Online
Supplementary Table S1).
Increased Bcl11b expression results in decreased 
proliferation of the myeloid cell line 32D(GCSF-R)
To investigate the effect of Bcl11b expression on prolif-
eration and differentiation, immortalized myeloblast-like
murine bone marrow cells stably expressing human
GCSF-R [32D(GCSF-R)] were transfected with full-length
murine Bcl11b cDNA. Three 32D(GCSF-R) clones express-
ing Bcl11b were selected and incubated for 10 days in the
presence of interleukin-3 or granulocyte colony-stimulat-
ing factor. Western blot analyses demonstrated that
BCL11B was expressed at all time points (Figure 7A).
BCL11B-expressing 32D(GCSF-R) clones showed a consis-
S. Abbas et al.
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Figure 6. Western blot analyses for
BCL11B primary AML. Immuno-detection
of the BCL11B protein in AML cases with
elevated levels of BCL11B mRNA (+) and
cases with undetectable levels of BCL11B
mRNA (-) (upper panel; Jurkat cell lysate
as positive control). GAPDH was used as
the loading control (lower panel).   
Figure 7. Effects of BCL11B overexpression in murine 32D(GCSF-R)  cells. (A) Western blot analyses for BCL11B in 32D(GCSFR) cells.
32D(GCSFR) clones overexpressing BCL11B are indicated by #2, #4, and #12 (interleukin 3 for 1 and 10 days). Lysates obtained from these
clones were immunostained for BCL11B at day 1 and day 10 [Jurkat cells: positive control; 32D: 32D(GCSF-R) cells]. GAPDH was used as the
loading control (lower panel). (B) Growth curve of 32D(GCSFR) cells with (squares, dashed line) and without (round, solid line) BCL11B expres-
sion and parental 32D(GCSFR) cells (triangles, dotted line) incubated with interleukin 3. 32D cells were counted every 24 h for 10 days. (C)
May-Grünwald-Giemsa-stained cytospins of 32D(GCSF-R) cells with (upper panel) and without (lower panel) BCL11B expression incubated with
granulocyte colony-stimulating factor for 7 days.  Granulocytic differentiation is monitored by the presence of cells with segmented nuclei.     
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tent decreased proliferation rate when cultured in the
presence of interleukin in comparison to 32D(GCSF-R)
clones containing a control, empty vector (Figure 7B). 
We also evaluated the granulocytic differentiation abili-
ties of the same 32D(GCSF-R) clones upon stimulation
with granulocyte colony-stimulating factor.
Morphological analyses of cytospins did not show consis-
tent maturation defects in the BCL11B-expressing
32D(GCSF-R) clones. However, less maturation towards
granulocytes in 32D(GCSF-R) cells expressing BCL11B
and more undifferentiated blast cells compared to cells
with empty vector were present in some 32D(GCSF-R)
BCL11B- expressing clones (Figure 7C). This effect was
most apparent in 32D(GCSF-R) BCL11B clones #4 and
#12, the 32D(GCSF-R) clones with the highest expression
levels of BCL11B (Figure 7A).
Discussion
Simultaneous analyses of genome-wide genotyping
and copy number data with gene expression profiling
enable the identification of pathogenic genes that, as a
result of genomic imbalances, are aberrantly expressed.
By an integrated approach involving genome-wide geno-
typing and gene expression profiling, we identified
BCL11B as a novel oncogene in AML. Interstitial amplifi-
cation of 14q32 was initially revealed in two AML cases
(#2301 and #7073) by genome-wide genotyping, showing
relatively small amplifications, including the BCL11B
gene. Although other genes were affected by these
numerical genetic changes, these 14q32 aberrations
resulted in unique BCL11B mRNA and full-length
BCL11B protein overexpression. By FISH of a selection of
40 AML cases with high BCL11B mRNA expression, we
identified two additional AML cases bearing BCL11B
translocations (AML #6451 and AML #6366).
The BCL11 family has two members, BCL11A and
BCL11B.18 Bcl11a was identified as a common retroviral
insertion site (Evi9) in murine myeloid leukemias and is
required for normal B-cell development.26 Mice carrying
biallelic inactivation of Bcl11b developed thymic lym-
phomas, indicating that loss-of-function mutations in
Bcl11b contribute to mouse lymphomagenesis and, possi-
bly, to human cancer development.27 BCL11B is a four-
exon gene located on 14q32, encoding a Kruppel family
zinc finger transcription factor and a key regulator of dif-
ferentiation and survival of thymocytes.18
BCL11B was first associated with hematologic malig-
nancies due to its recurrent involvement with the homeo -
box transcription factor TLX3 in a relatively high percent-
age of cases of pediatric and adult T-cell acute lym-
phoblastic leukemia carrying the cryptic
t(5;14)(q35;q32).28,29 Less frequently, T-cell acute lym-
phoblastic leukemia samples with an
inv(14)(q11.2q32.31) carry an in-frame transcript of
BCL11B and the T-cell receptor gene segment TRDV1.
These cases of acute lymphoblastic leukemia do not
express wild-type BCL11B transcripts, suggesting that
BCL11B disruption may contribute to T-cell malignancies
in humans.30 Interestingly, a DNA copy number and
sequencing analysis approach recently revealed mono-
allelic BCL11B deletions and missense mutations in 10-
15% of cases of T-cell acute lymphoblastic leukemia.31,32
Structural homology modeling showed that several of the
BCL11B mutations disrupted the structure of zinc finger
domains required for DNA binding.
A number of myeloid, mixed-lineage, and non-lympho-
cytic leukemias with 14q32 abnormalities have been
reported, however, in these instances the affected genes
were not identified.33-37 The first evidence of BCL11B
involvement in 14q32 translocations in AML was report-
ed by Bezrookove et al.34 These authors reported one case
of t(6;14)(q25~q26;q32) in an adult with AML and used
bacterial artificial chromosomes to demonstrate the
involvement of BCL11B in that case.34 Due to a lack of the
patient’s material, the investigators could neither estab-
lish the deregulation of BCL11B nor identify the partner
genomic locus.34 Of note, the breakpoint in this AML case
appeared to be located upstream of the BCL11B gene.
This resembles the AML cases described here and sug-
gests that the breakpoints in AML are clustered upstream,
whereas in acute lymphoblastic leukemia they are down-
stream, of BCL11B. 
Specific chromosomal paints demonstrated that differ-
ent partner chromosomes were involved in the AML
cases with a BCL11B translocation. The fact that in two
AML cases the BCL11B-containing amplified region inte-
grated in transcriptionally active large non-coding RNA
may suggest that different regulatory regions of large
non-coding RNA are capable of activating the BCL11B
oncogene in these cases of AML. The breakpoints in AML
#2301 and #7073 are 10 kb and 600 kb away from the
transcriptional start site of BCL11B. There is no obvious
reason why BCL11B specifically, and not the other genes,
would be activated. Interestingly, however, the
rearranged BCL11B allele in both AML #2301 and AML
#7073 is juxtaposed to recently described super-
enhancers, which have been shown to act as key onco-
genic drivers.38,39 These putative super-enhancers are pres-
ent in the cell line MOLM-1 and seem to be linked to
ARID1B on chromosome 6 (#2301) and GSDMC on chro-
mosome 8 (#7073) and may be responsible for increased
BCL11B expression. The selective overexpression of
BCL11B may give the cells a specific advantage, whereas
the other genes located on 14q32 would not. 
Interestingly, BCL11B protein appeared to be expressed
in additional cases of primary AML that do not carry
BCL11B translocations. In these AML cases other muta-
tions may be present or BCL11B may be activated by
other means.
The 14q32 region, including BCL11B, is subject to
translocation in T-cell acute lymphoblastic leukemia and
acute mixed lineage leukemia.23,33-37 In fact, the involve-
ment of 14q32 translocations and BCL11B in AML has
been debated.40 However, the immunophenotyping and
molecular analyses of the AML samples with BCL11B
translocations described here showed that these
leukemias have a biphenotypic immunophenotype, but
also all carry a common AML-associated FLT3 ITD muta-
tion. These leukemias do, therefore, share a characteristic
genetic feature with AML. 
BCL11B is expressed in T-lymphocytes and T-cell
leukemias and is a pivotal regulator of number of genes
related to T-cell proliferation and differentiation such as
IL2, NF-kappaB, TCRβ and p21.41-45 It was shown recently
that the expression of BCL11B in T-cell lines resulted in
markedly increased apoptosis resistance following treat-
ment with radiomimetic drugs accompanied by a cell cycle
delay caused by accumulation of cells at G1.46 We exam-
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ined the consequences of Bcl11b overexpression on prolif-
eration and differentiation in a mouse myeloid 32D(GCSF-
R) cell line model. The 32D(GCSF-R) cells, expressing full-
length murine Bcl11b cDNA, had a consistently decreased
proliferation rate compared to cells expressing the empty
vector or to the parental untransfected cells. Upon stimula-
tion with granulocyte colony-stimulating factor,
32D(GCSF-R) cells overexpressing Bcl11b showed less
maturation towards granulocytes compared to cells
expressing empty vector, giving supporting evidence that
BCL11B is partially blocking or delaying differentiation in
32D(GCSF-R)  cells. The decreased proliferation rate in
BCL11B-expressing cells suggests that a proliferative muta-
tion, such as a FLT3-ITD, may indeed be required for full-
leukemic transformation.
In conclusion, we have shown that BCL11B is involved
in 14q32 translocations with different putative chromoso-
mal partners in well-characterized AML cases using high-
throughput genome-wide genotyping, cytogenetics and
gene expression profiling. In these translocations, full-
length BCL11B is highly expressed concomitantly with T-
cell specific markers. We speculate that due to the translo-
cations, BCL11B expression is influenced by active tran-
scriptional elements on the partner chromosomes result-
ing in high BCL11B expression and consequently T-cell
associated genes. The murine cell line 32D(GCSF-R) over-
expressing BCL11B shows decreased proliferation and
partial delayed differentiation, which provides evidence
that BCL11B may have suppressive and disruptive effects
on cell proliferation and differentiation of myeloid cells.
Altogether, these analyses indicate that BCL11B is a puta-
tive oncogene in AML with and possibly without aberra-
tions involving 14q32.
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